<DOC>
	<DOCNO>NCT01248780</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy golimumab Chinese patient rheumatoid arthritis .</brief_summary>
	<brief_title>Study Subcutaneous Golimumab Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy</brief_title>
	<detailed_description>Golimumab type tumor necrosis factor ( TNF ) -inhibitor . TNF naturally occur substance body , substance may cause long-term inflammation . Golimumab may help fight disease block activity TNF body reduce inflammation pain . Each patient allow join study put group randomly , like flip coin . Patients may get either golimumab placebo ( look like drug study active ingredient , example sugar pill ) . The chance patient get golimumab 1 1 , 50 % chance receive golimumab 50 % chance receive placebo . If patient improvement joint Week 16 visit compare enter study , Group 1 ( placebo group ) , patient receive golimumab 50 mg every 4 week start Week 16 . If patient Group 2 ( golimumab 50 mg ) , patient continue receive golimumab every 4 week start Week 16 . If patient Group 1 still receive placebo injection , improvement joint Week 16 , patient receive golimumab 50 mg every 4 week start Week 24 . If patient Group 2 ( golimumab 50 mg ) already receive golimumab injection week 24 , patient continue receive golimumab every 4 week . Safety monitor throughout study , include draw blood look laboratory test , vital sign ( e.g. , blood pressure ) , frequency type adverse event ( side effect ) . The patient study approximately 56 week . Patients receive placebo active compound ( golimumab 50 mg subcutaneous injection ) every four week randomization ( Week 0 ) Week 48 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis least 6 month Be stable dose methotrexate 4 week Have least 4 swollen 4 tender joint Prior exposure biologic antiTNFalpha agent Inflammatory disease rheumatoid arthritis Treatment Disease Modifying Antirheumatic drug ( DMARDs ) /systemic immunosuppressive methotrexate 4 week prior first administration study agent History , ongoing , chronic recurrent infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>injection</keyword>
	<keyword>golimumab</keyword>
	<keyword>simponi</keyword>
</DOC>